de Jonge C - Search Results

1

Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes.

de Jonge C, Rensen SS, D'Agnolo HM, Bouvy ND, Buurman WA, Greve JW. de Jonge C, et al. Obes Surg. 2014 Feb;24(2):337-41. doi: 10.1007/s11695-013-1154-1. Obes Surg. 2014. PMID: 24357127

2

Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes.

de Jonge C, Fuentes S, Zoetendal EG, Bouvy ND, Nelissen R, Buurman WA, Greve JW, de Vos WM, Rensen SS. de Jonge C, et al. Among authors: de vos wm. Int J Obes (Lond). 2019 Dec;43(12):2509-2517. doi: 10.1038/s41366-019-0336-x. Epub 2019 Feb 14. Int J Obes (Lond). 2019. PMID: 30765893

3

Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease.

de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, Greve JW. de Jonge C, et al. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1517-20. doi: 10.1016/j.cgh.2013.07.029. Epub 2013 Aug 3. Clin Gastroenterol Hepatol. 2013. PMID: 23920034

4

Human intestinal microbiota composition is associated with local and systemic inflammation in obesity.

Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM, Rensen SS. Verdam FJ, et al. Among authors: de jonge c, de vos wm. Obesity (Silver Spring). 2013 Dec;21(12):E607-15. doi: 10.1002/oby.20466. Epub 2013 Jun 22. Obesity (Silver Spring). 2013. PMID: 23526699 Free article.

5

Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.

de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Schaper NC, Bouvy ND, Greve JW. de Jonge C, et al. Obes Surg. 2013 Sep;23(9):1354-60. doi: 10.1007/s11695-013-0921-3. Obes Surg. 2013. PMID: 23526068

6

The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.

Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. Koehestanie P, et al. Among authors: de jonge c. Ann Surg. 2014 Dec;260(6):984-92. doi: 10.1097/SLA.0000000000000794. Ann Surg. 2014. PMID: 25072436 Clinical Trial.

7

Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans.

van Nierop FS, de Jonge C, Kulik W, Bouvy N, Schaap FG, Olde Damink SW, Rensen S, Romijn JA, Greve JWM, Soeters MR. van Nierop FS, et al. Among authors: de jonge c. Metabolism. 2019 Apr;93:25-32. doi: 10.1016/j.metabol.2018.12.009. Epub 2019 Jan 15. Metabolism. 2019. PMID: 30658059

8

Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial.

van Rijn S, Roebroek YGM, de Jonge C, Greve JWM, Bouvy ND. van Rijn S, et al. Among authors: de jonge c. Obes Surg. 2019 Apr;29(4):1117-1121. doi: 10.1007/s11695-018-03659-6. Obes Surg. 2019. PMID: 30627989 Clinical Trial.

9

Impact of Duodenal-Jejunal Exclusion on Satiety Hormones.

de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA, le Roux CW, Bouvy ND, Greve JW. de Jonge C, et al. Obes Surg. 2016 Mar;26(3):672-8. doi: 10.1007/s11695-015-1889-y. Obes Surg. 2016. PMID: 26446491

10

The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.

van Rijn S, Betzel B, de Jonge C, van Dijk DPJ, Janssen IM, Berends FJ, Bouvy ND, Greve JWM. van Rijn S, et al. Among authors: de jonge c. Obes Surg. 2018 May;28(5):1255-1262. doi: 10.1007/s11695-017-2997-7. Obes Surg. 2018. PMID: 29110244 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results